Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

• DOI: 10.3389/fmed.2023.1073025
• Publication Date: 2023-02-07T06:31:57Z
• Authors: Ryosuke Sugimoto; Motoh Iwasa; Akiko Eguchi; Yasuyuki Tamai; Ryuta Shigefuku; Naoto Fujiwara; Hideaki Tanaka; Yoshinao Kobayashi; Jiro Ikoma; Masahiko Kaito; Hayato Nakagawa
• Keywords: Dyslipidemia; Alanine aminotransferase

Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. was reported to reduce ALT non-alcoholic fatty liver disease (NAFLD) patients, but efficacy not clearly elucidated due the small size of previous study populations. Therefore, we explored pemafibrate NAFLD patients.We retrospectively evaluated on enzymes (n = 132) and shear wave velocity (SWV, n 51) patients who had taken for at least 24 weeks.Patient levels were decreased from 81.0 IU/L baseline 48.0 week (P < 0.0001). Serum aspartate (AST), γ-glutamyl transpeptidase (γ-GTP) triglyceride (TG) significantly decreased, high-density lipoprotein cholesterol platelet count increased, with no change body weight being observed. Study participant SWV values 1.45 m/s 1.32 48 0.001). Older age 0.035) TG 0.048) associated normalized ALT. Changes AST, ALT, γ-GTP correlated SWV.Pemafibrate function, stiffness promising therapeutic agent may be candidate elevated TG.